重组
RabMAb

Anti-Tau (phospho S396)抗体[EPR2731] (ab109390)

概述

  • 产品名称
    Anti-Tau (phospho S396)抗体[EPR2731]
    参阅全部 Tau 一抗
  • 描述
    兔单克隆抗体[EPR2731] to Tau (phospho S396)
  • 特异性
    This antibody only detects Tau phosphorylated at serine 396.
  • 经测试应用
    适用于: Dot blot, IHC-P, WBmore details
    不适用于: ICC/IF or IP
  • 种属反应性
    与反应: Mouse, Rat, Human
  • 免疫原

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Tau aa 350 to the C-terminus.
    Database link: P10636-8

  • 阳性对照
    • WB: SH-SY5Y treated with alkaline phosphatase, Mouse brain. ICC/IF: Neuro-2a IHC-P: human glioblastoma, human Alzheimer hippocampus
  • 常规说明

    A trial size is available to purchase for this antibody.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

性能

应用

Our Abpromise guarantee covers the use of ab109390 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
Dot blot 1/1000.
IHC-P 1/4000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
WB 1/10000 - 1/50000. Predicted molecular weight: 79 kDa.Can be blocked with Human Tau (phospho S396) peptide (ab226770).

For unpurified, use 1/10000 - 1/50000.

  • 应用说明
    Is unsuitable for ICC/IF or IP.
  • 靶标

    • 功能
      Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
    • 组织特异性
      Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
    • 疾病相关
      Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
      Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
      Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
      Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
      Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
    • 序列相似性
      Contains 4 Tau/MAP repeats.
    • 发展阶段
      Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
    • 结构域
      The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
    • 翻译后修饰
      Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
      Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
      Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
    • 细胞定位
      Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
    • Information by UniProt
    • 数据库链接
    • 形式
      There are 9 isoforms produced by alternative splicing.
    • 别名
      • AI413597 antibody
      • AW045860 antibody
      • DDPAC antibody
      • FLJ31424 antibody
      • FTDP 17 antibody
      • G protein beta1/gamma2 subunit interacting factor 1 antibody
      • MAPT antibody
      • MAPTL antibody
      • MGC134287 antibody
      • MGC138549 antibody
      • MGC156663 antibody
      • Microtubule associated protein tau antibody
      • Microtubule associated protein tau isoform 4 antibody
      • Microtubule-associated protein tau antibody
      • MSTD antibody
      • Mtapt antibody
      • MTBT1 antibody
      • MTBT2 antibody
      • Neurofibrillary tangle protein antibody
      • Paired helical filament tau antibody
      • Paired helical filament-tau antibody
      • PHF tau antibody
      • PHF-tau antibody
      • PPND antibody
      • PPP1R103 antibody
      • Protein phosphatase 1, regulatory subunit 103 antibody
      • pTau antibody
      • RNPTAU antibody
      • TAU antibody
      • TAU_HUMAN antibody
      • Tauopathy and respiratory failure, included antibody
      see all

    Anti-Tau (phospho S396) antibody [EPR2731] 图像

    • IHC image of Tau (phospho S396) staining in human Alzheimer hippocampus formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with citrate buffer. The section was then incubated with unpurified ab109390 at 1/1000 dilution for 2 hoursat 21ºC. A biotin conjugated goat-anti-rabbit antibody was used as a secondary at 1/250. The section shows clear neurofibrillary tangles in a subset of neurons.

      See Abreview

    • Immunohistochemical staining of paraffin embedded human glioblastoma with purified ab109390 at a dilution of 1/4000. A pre-diluted HRP polymer for rabbit/mouse IgG was used as the secondary antibody and the sample was counter-stained wirh hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.

    • All lanes : Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/20000 dilution

      Lane 1 : Human brain whole cell lysates.
      Lane 2 : Human brain whole cell lysates. The membrane was incubated with phosphatase.

      Lysates/proteins at 15 µg per lane.

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size : 79 kDa


      Exposure time : 1 minute

      Diluting and blocking buffer: 5% NFDM/TBST

    • All lanes : Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/20000 dilution (purified)

      Lane 1 : Untreated SH-SY5Y
      Lane 2 : SH-SY5Y treated with alkaline phosphatase

      Lysates/proteins at 10 µg per lane.

      Secondary
      HRP goat ant-rabbit (H+L) at 1/1000 dilution

      Predicted band size : 79 kDa
      Observed band size : 50-70 kDa (why is the actual band size different from the predicted?)

      Blocking buffer: 5% NFDM/TBST

      Dilution buffer: 5% NFDM/TBST

    • Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/5000 dilution (purified) + Mouse brain at 10 µg

      Secondary
      HRP goat anti-rabbit (H+L) at 1/1000 dilution

      Predicted band size : 79 kDa
      Observed band size : 50-70 kDa (why is the actual band size different from the predicted?)

      Blocking buffer: 5% NFDM/TBST

      Dilution buffer: 5% NFDM/TBST

    • Dot blot analysis of Tau (phospho S396) phospho peptide (Lane 1) and Tau non-phospho peptide (Lane 2) labeling Tau (phospho S396) with ab109390 at a dilution of 1/1000. ab97051 (Peroxidase conjugated goat anti-rabbit IgG) (H+L) at 1/100 000 was used as the secondary antibody.

      Blocking and diluting buffer: 5% NFDM/TBST.

      Exposure time: 3 minutes.

    • All lanes : Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/10000 dilution (unpurified)

      Lane 1 : SH-SY5Y cell lysates, untreated
      Lane 2 : SH-SY5Y cell lysates, treated with Alkaline Phosphatase

      Lysates/proteins at 10 µg per lane.


      Predicted band size : 79 kDa

    Anti-Tau (phospho S396) antibody [EPR2731] (ab109390)参考文献

    This product has been referenced in:
    • Sadick JS  et al. Protein characterization of intracellular target-sorted, formalin-fixed cell subpopulations. Sci Rep 6:33999 (2016). WB, ICC/IF ; Human . Read more (PubMed: 27666089) »
    • Guo C  et al. Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse model. Sci Rep 6:29396 (2016). Read more (PubMed: 27406855) »

    See all 8 Publications for this product

    Product Wall

    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Sample
    Dog Tissue sections (Brain)
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: citrate buffer
    Specification
    Brain
    Blocking step
    BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10%
    Fixative
    Formaldehyde
    Username

    Tom Duncan

    Verified customer

    提交于 Oct 18 2017

    Application
    ELISA
    Sample
    Mouse Tissue sections (Cortex protein lysate)
    Specification
    Cortex protein lysate
    Blocking step
    BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 2% · Temperature: 18°C
    Type
    Sandwich (Detection)
    Username

    Dr. Eitan Okun

    Verified customer

    提交于 Aug 23 2016

    Application
    Immunohistochemistry (Frozen sections)
    Sample
    Mouse Tissue sections (Brain)
    Permeabilization
    Yes - Buffer solutions for heat-induced epitope retrieval
    Specification
    Brain
    Blocking step
    Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 20% · Temperature: rt°C
    Fixative
    Paraformaldehyde
    Username

    Dr. Eitan Okun

    Verified customer

    提交于 Apr 18 2016

    Application
    Western blot
    Loading amount
    10 µg
    Gel Running Conditions
    Reduced Denaturing (10%)
    Sample
    Human Cell lysate - whole cell (human stem cell derived neurons (healthy/diseased))
    Specification
    human stem cell derived neurons (healthy/diseased)
    Treatment
    quinolinic acid 72h (and non treated)
    Blocking step
    BSA as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: rt°C
    Username

    Abcam user community

    Verified customer

    提交于 Mar 26 2014

    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Blocking step
    (agent) for 10 minute(s) · Concentration: 1% · Temperature: 21°C
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: Citric acid
    Sample
    Human Tissue sections (Brain)
    Specification
    Brain
    Permeabilization
    No
    Fixative
    Formaldehyde
    Username

    Mr. Carl Hobbs

    Verified customer

    提交于 Dec 12 2013

    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Blocking step
    BSA as blocking agent for 10 minute(s) · Concentration: 1% · Temperature: 21°C
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: Citric acid
    Sample
    Human Tissue sections (Tau/APP transgenic mouse brain expressing human Ta)
    Specification
    Tau/APP transgenic mouse brain expressing human Ta
    Permeabilization
    No
    Fixative
    Formaldehyde
    Username

    Mr. Carl Hobbs

    Verified customer

    提交于 Dec 12 2013

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    注册